Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
37.25 (1y: +14%)
Market Cap 1.1 B P/E(ttm) 182.60
Enterprise Value 1.01 B P/B 8.87
GHDX- NAS (USA)
Genomic Health, Inc.
Not Rated
Top Ranked Predictable Companies
$37.25
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry		 vs
history
Cash to Debt No Debt
GHDX's Cash to Debt is ranked higher than
70% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 16.56 vs. GHDX: No Debt )
GHDX' s 10-Year Cash to Debt Range
Min: 5.13   Max: No Debt
Current: No Debt
Equity to Asset 0.822
GHDX's Equity to Asset is ranked higher than
94% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.50 vs. GHDX: 0.822 )
GHDX' s 10-Year Equity to Asset Range
Min: -3.02   Max: 0.89
Current: 0.82
-3.02
0.89
Interest Coverage No Debt
GHDX's Interest Coverage is ranked higher than
70% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 66.20 vs. GHDX: No Debt )
GHDX' s 10-Year Interest Coverage Range
Min: No Debt   Max: No Debt
Current: No Debt
F-Score: 5
Z-Score: 26.17
M-Score: -2.37
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry		 vs
history
Operating margin (%) 3.60
GHDX's Operating margin (%) is ranked higher than
57% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.10 vs. GHDX: 3.60 )
GHDX' s 10-Year Operating margin (%) Range
Min: -12348   Max: 4
Current: 3.6
-12348
4
Net-margin (%) 3.5
GHDX's Net-margin (%) is ranked higher than
64% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. GHDX: 3.5 )
GHDX' s 10-Year Net-margin (%) Range
Min: -12200   Max: 3.8
Current: 3.5
-12200
3.8
ROE (%) 6.5
GHDX's ROE (%) is ranked higher than
67% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.00 vs. GHDX: 6.5 )
GHDX' s 10-Year ROE (%) Range
Min: -69.1   Max: 6.8
Current: 6.5
-69.1
6.8
ROA (%) 5.4
GHDX's ROA (%) is ranked higher than
74% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.40 vs. GHDX: 5.4 )
GHDX' s 10-Year ROA (%) Range
Min: -116.4   Max: 5.5
Current: 5.4
-116.4
5.5
ROC (Joel Greenblatt) (%) 42.40
GHDX's ROC (Joel Greenblatt) (%) is ranked higher than
89% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.00 vs. GHDX: 42.40 )
GHDX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4128.4   Max: 69.8
Current: 42.4
-4128.4
69.8
Revenue Growth (%) 10.3
GHDX's Revenue Growth (%) is ranked higher than
90% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.40 vs. GHDX: 10.3 )
GHDX' s 10-Year Revenue Growth (%) Range
Min: 10.3   Max: 88.3
Current: 10.3
10.3
88.3
ยป GHDX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

GHDX Guru Trades in Q2 2012

Manning & Napier Advisors, Inc 341,531 sh (New)
Steven Cohen 12,344 sh (New)
Jim Simons 186,800 sh (+76.89%)
» More
Q3 2012

GHDX Guru Trades in Q3 2012

Paul Tudor Jones 20,400 sh (New)
Jim Simons 274,500 sh (+46.95%)
Steven Cohen 12,800 sh (+3.69%)
Manning & Napier Advisors, Inc 351,391 sh (+2.89%)
» More
Q4 2012

GHDX Guru Trades in Q4 2012

Chuck Royce 40,000 sh (New)
David Swensen 37,861 sh (New)
Manning & Napier Advisors, Inc Sold Out
Paul Tudor Jones 20,300 sh (-0.49%)
Jim Simons 231,600 sh (-15.63%)
Steven Cohen 2,815 sh (-78.01%)
» More
Q1 2013

GHDX Guru Trades in Q1 2013

Steven Cohen 7,164 sh (+154.49%)
Jim Simons 269,500 sh (+16.36%)
Chuck Royce 40,000 sh (unchged)
David Swensen Sold Out
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with GHDX

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
David Swensen 2013-03-31 Sold Out 2.8%$26.72 - $29.65 $ 37.2531%0
David Swensen 2012-12-31 New Buy2.8%$26.42 - $36.8 $ 37.2524%37861
David Swensen 2011-03-31 Sold Out 0.93%$21.08 - $26.18 $ 37.2560%0
David Swensen 2010-12-31 New Buy0.93%$13.18 - $23.52 $ 37.25110%38243
Premium More recent guru trades are included for Premium Members only!!

Top Ranked Articles about Genomic Health, Inc.

CEO of InVitae Corporation of Genomic Health Inc. Randal W. Scott Sold 30,000 Shares
July 13, 2012
Genomic Health Inc. is a life science company focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. Genomic Health Inc. has a market cap of $1.09 billion; its shares were traded at around $35.12 with a P/E ratio of 129.4 and P/S ratio of 5.3. Read more...

Ratios

vs
industry		 vs
history
P/E(ttm) 182.60
GHDX's P/E(ttm) is ranked higher than
50% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.95 vs. GHDX: 182.60 )
GHDX' s 10-Year P/E(ttm) Range
Min: 2.02   Max: 261
Current: 182.6
2.02
261
P/B 8.87
GHDX's P/B is ranked lower than
76% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.61 vs. GHDX: 8.87 )
GHDX' s 10-Year P/B Range
Min: 3.29   Max: 14.31
Current: 8.87
3.29
14.31
P/S 4.86
GHDX's P/S is ranked lower than
64% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.22 vs. GHDX: 4.86 )
GHDX' s 10-Year P/S Range
Min: 2.17   Max: 20.45
Current: 4.86
2.17
20.45
PFCF 98.03
GHDX's PFCF is ranked lower than
59% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.30 vs. GHDX: 98.03 )
GHDX' s 10-Year PFCF Range
Min: 33.81   Max: 521
Current: 98.03
33.81
521
EV-to-EBIT 151.07
GHDX's EV-to-EBIT is ranked lower than
54% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.90 vs. GHDX: 151.07 )
GHDX' s 10-Year EV-to-EBIT Range
Min: 78.7   Max: 205.2
Current: 151.07
78.7
205.2
Shiller P/E 38
GHDX's Shiller P/E is ranked lower than
71% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 12.19 vs. GHDX: 38 )
GHDX' s 10-Year Shiller P/E Range
Min: 21.11   Max: 109.62
Current: 38
21.11
109.62

Valuation & Return

vs
industry		 vs
history
Price/Net Cash 15.6
GHDX's Price/Net Cash is ranked higher than
82% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.65 vs. GHDX: 15.6 )
GHDX' s 10-Year Price/Net Cash Range
Min: 6.5   Max: 16.5
Current: 15.6
6.5
16.5
Price/Net Current Asset Value 58.7
GHDX's Price/Net Current Asset Value is ranked higher than
89% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 14.40 vs. GHDX: 58.7 )
GHDX' s 10-Year Price/Net Current Asset Value Range
Min: 41.4   Max: 188.5
Current: 58.7
41.4
188.5
Price/Tangible Book 8.8
GHDX's Price/Tangible Book is ranked higher than
84% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.00 vs. GHDX: 8.8 )
GHDX' s 10-Year Price/Tangible Book Range
Min: 1   Max: 11
Current: 8.8
1
11
Price/DCF (Projected) 8
GHDX's Price/DCF (Projected) is ranked higher than
97% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.30 vs. GHDX: 8 )
GHDX' s 10-Year Price/DCF (Projected) Range
Min: 5.9   Max: 39.1
Current: 8
5.9
39.1
Price/Median PS Value 1.1
GHDX's Price/Median PS Value is ranked higher than
77% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.90 vs. GHDX: 1.1 )
GHDX' s 10-Year Price/Median PS Value Range
Min: 0.7   Max: 3.3
Current: 1.1
0.7
3.3
Price/Graham Number 7.3
GHDX's Price/Graham Number is ranked higher than
98% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.80 vs. GHDX: 7.3 )
GHDX' s 10-Year Price/Graham Number Range
Min: 5.4   Max: 7
Current: 7.3
5.4
7
Earnings Yield (Greenblatt) 0.70
GHDX's Earnings Yield (Greenblatt) is ranked higher than
57% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.60 vs. GHDX: 0.70 )
GHDX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.5   Max: 1.3
Current: 0.7
0.5
1.3
Forward Rate of Return (Yacktman) 0.24
GHDX's Forward Rate of Return (Yacktman) is ranked higher than
96% of the 90 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.46 vs. GHDX: 0.24 )
GHDX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -27.5   Max: 0.4
Current: 0.24
-27.5
0.4

Business Description

Genomic Health, Inc. was incorporated in Delaware in August 2000. Genomic Health is a global cancer company focusing on advanced molecular diagnostics. It develops and globally commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions. Its Oncotype DX platform utilizes quantitative genomic analysis known as reverse transcription polymerase chain reaction, or RT-PCR, in standard tumor pathology specimens to provide tumor-specific information, or the 'Oncotype' of a tumor. The Company offers its Oncotype DX tests as a clinical service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, for invasive breast cancer and colon cancer and a DCIS Score for DCIS. The Company's Oncotype DX breast cancer test analyzes the expression levels of 21 genes and its Oncotype DX colon cancer test analyzes the expression levels of 12 genes. All of the testing services are made available through its clinical reference laboratory located in Redwood City, California. The Company's research and development activities are focused on developing a pipeline of tests to optimize the treatment of prostate and renal cell cancers, as well as additional treatment decisions in breast and colon cancers.
Company Website
SEC Reports
Industry: Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ
Traded in other countries:G7H.Germany
ยป More Articles for GHDX

Headlines

Articles On GuruFocus.com
CEO of InVitae Corporation of Genomic Health Inc. Randal W. Scott Sold 30,000 Shares Jul 13 2012 
Yale Endowment Fund Loads Up EEM May 13 2011 
Genomic Health Inc. (GHDX) President and CEO Kimberly J Popovits sells 8,000 Shares Mar 16 2011 
Genomic Health Inc. (GHDX) CFO Dean L Schorno sells 1,000 Shares Mar 16 2011 
Genomic Health Inc. (GHDX) Executive Chairman Randal W Scott sells 20,000 Shares Mar 14 2011 
Genomic Health Inc. (GHDX) COO G Bradley Cole sells 2,500 Shares Mar 10 2011 
Genomic Health Inc. (GHDX) President and CEO Kimberly J Popovits sells 8,000 Shares Feb 16 2011 
Genomic Health Inc. (GHDX) President and CEO Kimberly J Popovits sells 8,000 Shares Feb 16 2011 
Genomic Health Inc. (GHDX) CFO Dean L Schorno sells 1,000 Shares Feb 16 2011 
Genomic Health Inc. (GHDX) Executive Chairman Randal W Scott sells 20,000 Shares Feb 14 2011 

More From Our Partners
Much Awaited Test Launch by Genomic - Analyst Blog May 15 2013 - ZACKS

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names
Free 7-day Trial